RAN-QUINAPRIL TABLET
Land: Kanada
Språk: engelska
Källa: Health Canada
Produktens egenskaper
(SPC)
30-06-2017
Vissa dokument för denna produkt är för närvarande inte tillgängliga, du kan skicka en begäran till vår kundservice och vi kommer att meddela dig så snart vi kan få dem.
Skicka förfrågan.
Skicka förfrågan.
Aktiva substanser:
QUINAPRIL (QUINAPRIL HYDROCHLORIDE)
Tillgänglig från:
RANBAXY PHARMACEUTICALS CANADA INC.
ATC-kod:
C09AA06
INN (International namn):
QUINAPRIL
Dos:
40MG
Läkemedelsform:
TABLET
Sammansättning:
QUINAPRIL (QUINAPRIL HYDROCHLORIDE) 40MG
Administreringssätt:
ORAL
Enheter i paketet:
30/1000
Receptbelagda typ:
Prescription
Terapiområde:
ANGIOTENSIN-CONVERTING ENZYME INHIBITORS
Produktsammanfattning:
Active ingredient group (AIG) number: 0123206004; AHFS:
Bemyndigande status:
APPROVED
Tillstånd datum:
2014-10-17
Produktens egenskaper
_Pr_
_RAN™-QUINAPRIL (Quinapril Tablets USP) Product Monograph_
_Page 1 of 39_
PRODUCT MONOGRAPH
PR
RAN
™
-QUINAPRIL
QUINAPRIL TABLETS USP
(5 MG, 10 MG, 20 MG AND 40 MG OF QUINAPRIL AS QUINAPRIL HYDROCHLORIDE)
ANGIOTENSIN CONVERTING ENZYME INHIBITOR
Ranbaxy Pharmaceuticals Canada Inc.
126 East Drive
Brampton, ON
L6T 1C1
Date of Revision:
June 22, 2017
CONTROL NO. 206533
RAN trademark owned by Sun Pharmaceutical Industries Ltd.
_Pr_
_RAN™-QUINAPRIL (Quinapril Tablets USP) Product Monograph_
_Page 2 of 39_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
............................................................ 3
SUMMARY PRODUCT INFORMATION
..........................................................................
3
INDICATIONS AND CLINICAL USE
................................................................................
3
CONTRAINDICATIONS
.....................................................................................................
4
WARNINGS AND PRECAUTIONS
....................................................................................
4
ADVERSE REACTIONS
....................................................................................................
11
DRUG INTERACTIONS
....................................................................................................
15
DOSAGE AND ADMINISTRATION
................................................................................
18
OVERDOSAGE
...................................................................................................................
20
ACTION AND CLINICAL PHARMACOLOGY
.............................................................. 20
STORAGE AND STABILITY
............................................................................................
23
DOSAGE FORMS, COMPOSITION ANDPACKAGING
................................................. 23
PART II: SCIENTIFIC INFORMATION
..................................................................................
24
PHARMACEUTICAL INFORMATION
......................
Läs hela dokumentet
